(Q37519645)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19527107%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

review article

1 reference

title

Overview of stem cell therapy for Crohn's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19527107%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19527107%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

author name string

Gerald Wayne Dryden

series ordinal

1

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 July 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19527107%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Biological Therapy

31 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19527107%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19527107%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19527107%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

page(s)

841-847

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19527107%20AND%20SRC:MED&resulttype=core&format=json

The fundamental basis of inflammatory bowel disease

31 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

Mucosal integrity and barrier function in the pathogenesis of early lesions in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

21 January 2018

Mesenchymal stem cells

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

Cardiomyocytes can be generated from marrow stromal cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

Mesenchymal stem cells can be differentiated into endothelial cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

Human mesenchymal stem cells modulate allogeneic immune cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

Conventional dendritic cells regulate the outcome of colonic inflammation independently of T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

Certolizumab pegol for the treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

Immunomodulation by mesenchymal stem cells and clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902956615

10.1517/14712590902956615

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19527107%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1 reference